# Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

> **NCT02654145** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 145 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Mepolizumab 100mg SC
- **DRUG:** Albuterol/salbutamol MDIs
- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT02654145
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-17
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654145, "Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02654145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*